A case report from a phase I clinical (NCT02122861, Table 2 (trial highlighted significant disease regression exceeding 85% in a patient with synovial sarcoma after receiving three intradermal injections of LV305, accompanied by a robust NY‐ESO‐1‐specific CD4+ and CD8+ T‐cell response that persisted for over 2.5 years post‐therapy. Here, CTAG1B is linked to synovial sarcoma.